Truth, lies, and statistical tests

AIDS Reader

Volumn 13, Issue 3, 2003, Pages 117-118+123

  Moyle, Graeme J ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Clinical trials; Evidence based medicine; HIV AIDS; Statistics

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; INDINAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE; ZIDOVUDINE PLUS LAMIVUDINE PLUS EFAVIRENZ;

ANALYTIC METHOD; ARTICLE; BIOAVAILABILITY; FOLLOW UP; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL PRACTICE; MEDICAL RESEARCH; PHYSICIAN; PROBABILITY; STATISTICAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

CLINICAL TRIALS; CONFIDENCE INTERVALS; HIV INFECTIONS; HUMANS; STATISTICS;

EID: 0037344174     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Gray JAM. Evidence-Based Healthcare. 2nd ed. Edinburgh: Churchill Livingstone; 2001.
2. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865-1873.
3. Squires KE, Thiry A, Giordano M, for the AI424-034 International Study Team. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed-dose ZDV+3TC: comparison of antiviral efficacy and safety through wk 24 (AI424-034). In: Program and abstracts of the 42nd Interscience Congress on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego. Abstract H-1076.
4. Robbins G, Shafer R, Smeaton L, et al. Antiretroviral strategies in naive HIV+ subjects: comparison of sequential 3-drug regimens (ACTG 384). In: Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract LbOr20A.
5. van Leth F, Hassink E, Phanuphak P, et al. The 2NN Study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine, efavirenz, or both drugs combined in addition to stavudine and lamivudine. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 1-14, 2003; Boston. Abstract LB.
6. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA. 2001;285:1155-1163.
7. Saag M, Cahn P, Raffi, et al. A randomized, double-blind, multicenter comparison of emtricitabine QD with stavudine BID. In: Program and abstracts of the 42nd Interscience Congress on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego. Abstract LB-1.
8. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996;313:36-39.